Abstract Number: 1540 • 2018 ACR/ARHP Annual Meeting
Validation of Hepatic Fibrosis Markers in People with Rheumatoid Arthritis on Methotrexate
Background/Purpose: MTX is the cornerstone of treatment of RA. A relatively rare side effect is liver fibrosis and cirrhosis, the incidence in patients on long-term…Abstract Number: 1541 • 2018 ACR/ARHP Annual Meeting
The Safety Profile of Iguratimod in Real Clinical Practice: Analysis of 491 Patients with Rheumatoid Arthritis
The retention rate and safty profile of iguratimod in real clinical practice: Analysis of 456 patients with Rheumatoid arthritis. Abstract Background/Purpose: Iguratimod is one of…Abstract Number: 1542 • 2018 ACR/ARHP Annual Meeting
Real-World Data from a Post-Approval Safety Surveillance Study of Tofacitinib Vs Biologic Dmards and Conventional Synthetic Dmards: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A prospective observational 5-year study, embedded within the US Corrona RA registry,…Abstract Number: 1543 • 2018 ACR/ARHP Annual Meeting
The Efficacy, Safety and Adherence of Biologicbiological Disease-Modifying Anti Rheumatic Drugs, Infliximab, Tocilizumab and Abatacept, in Elderly Patients with Rheumatoid Arthritis
Background/Purpose: Elderly patients with rheumatoid arthritis (RA) have declined physical performances and increased various complications. We are concerned about decrease of efficacy and increase of…Abstract Number: 1544 • 2018 ACR/ARHP Annual Meeting
Tofacitinib Safety and Efficacy in the Treatment of Rheumatoid Arthritis in a Central/Eastern European Subpopulation
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post hoc analysis assessed tofacitinib safety and efficacy in the Central…Abstract Number: 1545 • 2018 ACR/ARHP Annual Meeting
Exploring the Effects of Depressive Symptoms on the Efficacy of Sarilumab and Improvements in Health-Related Quality of Life
Background/Purpose: The pro-inflammatory cytokine IL-6 has been found to play a critical role in mood disorders, with symptoms such as anxiety and depression having implications…Abstract Number: 1546 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Corticosteroids in Rheumatoid Arthritis: Systematic Literature Review and Practical Recommendations
Background/Purpose: Corticosteroids are effective in rheumatoid arthritis (RA) patients but their adverse events limit their use. The aim of this study was to: 1) To…Abstract Number: 1547 • 2018 ACR/ARHP Annual Meeting
Impact of Obesity on Drug Survival of Tofacitinib in Patients with Rheumatoid Arthritis: Analysis from the Turkbio Registry
Background/Purpose: Several previous reports suggest that obesity impairs the effectiveness and drug survival of anti-TNF-α agents in rheumatoid arthritis (RA). The aim of the study…Abstract Number: 1548 • 2018 ACR/ARHP Annual Meeting
Favorable Effect of Hydroxychloroquine in Patients with Rheumatoid Arthritis and Diabetes or Impaired Glucose Control
Background/Purpose: Hydroxychloroquine (HCQ) is widely prescribed for patients with Rheumatoid Arthritis (RA) and Systemic Lupus Erythromatus (SLE). It is fairly well tolerated with multiple well…Abstract Number: 1549 • 2018 ACR/ARHP Annual Meeting
Comparison of Adverse Events and Survival of Treatment in Patients with Rheumatoid Arthritis Receiving Combined Treatment of Methotrexate and Leflunomide Versus Those Receiving Biological Therapy
Background/Purpose: According to clinical practice guidelines for patients with rheumatoid arthritis (RA), after failure to a c-DMARD (conventional disease modifying antirheumatic drug) can be chosen…Abstract Number: 1550 • 2018 ACR/ARHP Annual Meeting
Improvement of HbA1c in Patients with Rheumatoid Arthritis and Diabetes Type 2 during Treatment with Tocilizumab
Background/Purpose: Interleukin 6 (IL-6) and C-reactive protein (CRP) are independent risk factors for type 2 diabetes mellitus [1], and IL-6 plays a role in insulin…Abstract Number: 1551 • 2018 ACR/ARHP Annual Meeting
Anti-Drug Antibodies to Certolizumab Pegol Are Assiciated with Low Drug Levels and Reduced Clinical Response at 3 Months in Patients with Inflammatory Joint Diseases
Background/Purpose: Anti-drug antibodies (ADAb) to biological drugs predispose patients (pts) to low drug levels and lack of treatment response. For certolizumab pegol (CP) knowledge about…Abstract Number: 1552 • 2018 ACR/ARHP Annual Meeting
No Effect of Concomitant Glucocorticoid Therapy on Efficacy and Safety of Tocilizumab Monotherapy Found in Rheumatoid Arthritis Clinical Trials
No effect of concomitant glucocorticoid therapy on efficacy and safety of tocilizumab monotherapy in rheumatoid arthritis clinical trialsM. Safy1, J.W.G. Jacobs1, M. Edwardes2, M.J.H. de…Abstract Number: 1553 • 2018 ACR/ARHP Annual Meeting
An Analysis of Real-World Data on the Safety of Etanercept in Elderly Patients with Rheumatoid Arthritis
Background/Purpose: Both rheumatoid arthritis (RA) and older age are associated with a higher risk of comorbidities, and the appropriate treatment approach for older patients is…Abstract Number: 1554 • 2018 ACR/ARHP Annual Meeting
Cigarette Smoking Does Not Affect Treatment Response to Tofacitinib in Rheumatoid Arthritis
Background/Purpose: Smoking is one of the described risk factors for rheumatoid arthritis (RA) since smoking may induce citrullination of peptide antigens and thus the trigger…
ACR Meeting Abstracts